Acino Acquires Cephalon's Middle East and African Business - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Acino Acquires Cephalon's Middle East and African Business


ePT--the Electronic Newsletter of Pharmaceutical Technology

Switzerland’s Acino Pharma agreed to buy Cephalon’s combined Middle East and African business in a transaction worth approximately EUR 80 million ($110 million). Acino will pay EUR 60 million ($82.5 million) in cash, and an additional EUR 20 million ($27.5 million) will come through shares.

The acquired business includes both Cephalon and Mepha (a Swiss subsidiary of Cephalon) brands and is expected to generate sales of almost EUR 100 million ($137.4 million) in 2011. The product portfolio comprises the analgesic Olfen (diclofenac), the antispasmotic Spasfon (phloroglucinol–trimethylphloroglucinol), the gastrointestinal drug Gasec (omeprazole), and the antibiotic Mesporin (ceftriaxone).

The transaction will enable the company to make a “quantum leap” toward establishing its own presence in the emerging markets, according to a press statement from Acino. “Over the last 18 months, Acino’s management has refined its growth strategy to focus on three complementary business pillars: selling the products it develops through its partners in the developed markets, establishing its own market presence under its Acino Switzerland brand in emerging markets, and entering into development programs with innovative pharmaceutical companies based on its expertise in drug-delivery technology,” explained the Acino statement.

In related news, Cephlon has been acquired by Israel’s Teva Pharmaceutical Industries for approximately $6.8 billion. The deal was announced in May 2011, and received approval from EU authorities and US regulators last week. The approval from the European Commission, however, is conditional upon the divestment of Cephalon’s generic version of its Provigil drug.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here